Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals
11:30am, Thursday, 06'th Mar 2025
Axsome enters into a settlement agreement with Hikma Pharmaceuticals to resolve a patent litigation related to Sunosi.
AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug Filing
02:21pm, Tuesday, 04'th Mar 2025
Based on the FDA's feedback, Axsome plans to submit a supplemental NDA for AXS-05 in Alzheimer's disease agitation in third-quarter 2025.
On Monday, Axsome Therapeutics, Inc. AXSM announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP inhibitors
Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering
08:15am, Thursday, 20'th Feb 2025
Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering
Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth
12:30pm, Tuesday, 18'th Feb 2025
AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.
Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript
11:12am, Tuesday, 18'th Feb 2025
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q4 2024 Earnings Conference Call February 18, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - Chief
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
09:15am, Tuesday, 18'th Feb 2025
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.96 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.73 per share a year ago.
Axsome Therapeutics Revenue Surges 66%
08:06am, Tuesday, 18'th Feb 2025
Biopharmaceutical firm Axsome Therapeutics (AXSM -0.40%) reported mixed fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 18. The company achieved substantial revenue growth, with sales hitt
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?
10:30am, Monday, 17'th Feb 2025
Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?
09:45am, Sunday, 16'th Feb 2025
It's only mid-February, but as of this writing biotech company Axsome Therapeutics (AXSM -0.40%) is up by 55% year to date. Substantial stock-market gains over short periods aren't that rare in the in
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
05:20pm, Tuesday, 11'th Feb 2025
Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's Auvel
Why Axsome Therapeutics Stock Is Soaring Today
11:39am, Tuesday, 11'th Feb 2025
Shares of Axsome Therapeutics (AXSM 4.36%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m.
Earnings Preview: Axsome Therapeutics (AXSM) Q4 Earnings Expected to Decline
11:06am, Tuesday, 11'th Feb 2025
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva
08:41am, Tuesday, 11'th Feb 2025
AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038.
Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?
04:36am, Tuesday, 11'th Feb 2025
Axsome (AXSM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
